LifeSci Venture Partners

Team

Paul Yook    Partner & CIO   Paul has over 20 years of healthcare investment and finance experience and in 2017 founded LifeSci Venture Partners and serves as CIO and Portfolio Manager. In 2014, Paul launched the BioShares biotechnology ETFs (NYSE: BBC & BBP) which utilize innovative and sector-specific passive index strategies and have delivered the strongest performance metrics (Sharpe ratio and total return) in their class. He previously worked at Galleon Management, as a research analyst and healthcare hedge fund portfolio manager, and in the healthcare investment banking groups of Goldman Sachs and UBS.  Paul is a passionate surfer, having lived for 3 years in Hawaii, is a mediocre but improving chess player in an effort to keep up with his two young kids, and makes an outstanding açaí bowl. He earned a B.S.E in Economics from the Wharton School and a B.A. in Biochemistry from the College of Arts and Sciences at the University of Pennsylvania.

Paul Yook

Partner & CIO

Paul has over 20 years of healthcare investment and finance experience and in 2017 founded LifeSci Venture Partners and serves as CIO and Portfolio Manager. In 2014, Paul launched the BioShares biotechnology ETFs (NYSE: BBC & BBP) which utilize innovative and sector-specific passive index strategies and have delivered the strongest performance metrics (Sharpe ratio and total return) in their class. He previously worked at Galleon Management, as a research analyst and healthcare hedge fund portfolio manager, and in the healthcare investment banking groups of Goldman Sachs and UBS.

Paul is a passionate surfer, having lived for 3 years in Hawaii, is a mediocre but improving chess player in an effort to keep up with his two young kids, and makes an outstanding açaí bowl. He earned a B.S.E in Economics from the Wharton School and a B.A. in Biochemistry from the College of Arts and Sciences at the University of Pennsylvania.

Ryan Cinalli, PhD,     Chief Scientific Officer   Ryan has over 15 years of experience in the life sciences as an investment banker, research analyst and research scientist. Prior to joining LifeSci Partners in 2018, Ryan served as a member of the healthcare investment banking team at MTS Health Partners, where he advised leading biopharma companies on strategic and equity financing engagements. Prior to MTS, he was a research analyst at LifeSci Capital where he covered oncology, immunology and inflammation. Previously, he was a research scientist at Penn, NYU and Mount Sinai, where he worked with world class academic scientists, including Craig B. Thompson, Ruth Lehmann and Philippe Soriano, to identify novel therapeutic targets for oncology and regenerative medicine. His work has been presented at major medical meetings and published in leading scientific journals, including  Cell ,  Science  and  Nature .  Ryan holds an B.S. in Biochemistry from Stockton College and completed his Ph.D. research in a Howard Hughes laboratory at the NYU School of Medicine, where he was awarded an NSF Graduate Research Fellowship for his work.

Ryan Cinalli, PhD,

Chief Scientific Officer

Ryan has over 15 years of experience in the life sciences as an investment banker, research analyst and research scientist. Prior to joining LifeSci Partners in 2018, Ryan served as a member of the healthcare investment banking team at MTS Health Partners, where he advised leading biopharma companies on strategic and equity financing engagements. Prior to MTS, he was a research analyst at LifeSci Capital where he covered oncology, immunology and inflammation. Previously, he was a research scientist at Penn, NYU and Mount Sinai, where he worked with world class academic scientists, including Craig B. Thompson, Ruth Lehmann and Philippe Soriano, to identify novel therapeutic targets for oncology and regenerative medicine. His work has been presented at major medical meetings and published in leading scientific journals, including Cell, Science and Nature.

Ryan holds an B.S. in Biochemistry from Stockton College and completed his Ph.D. research in a Howard Hughes laboratory at the NYU School of Medicine, where he was awarded an NSF Graduate Research Fellowship for his work.

Ira Kalfus, MD    Chief Medical Officer   Dr. Kalfus was Chief Medical Officer at Thar Pharmaceuticals until its acquisition by Grunenthal in 2016. He was previously Vice President of Medical Affairs at Lev Pharmaceuticals, where he led the clinical development for Cinryze, the first HAE prophylaxis therapy, approved by the FDA in 2008. Upon the acquisition of Lev by ViroPharma Inc. in 2008, he consulted on the Cinryze commercial launch and expansion as well as investor relations activities for ViroPharma. Dr. Kalfus is consulting Medical Director at RedHill Biopharma Ltd. and directs two phase III clinical programs. His other positions have included Aetna/US Healthcare (Medical Director), Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement).   Dr. Kalfus completed residency in Internal Medicine at Long Island Jewish Medical Center and graduated from Albert Einstein College of Medicine with an M.D. and Columbia University with a B.A. in Biology.

Ira Kalfus, MD

Chief Medical Officer

Dr. Kalfus was Chief Medical Officer at Thar Pharmaceuticals until its acquisition by Grunenthal in 2016. He was previously Vice President of Medical Affairs at Lev Pharmaceuticals, where he led the clinical development for Cinryze, the first HAE prophylaxis therapy, approved by the FDA in 2008. Upon the acquisition of Lev by ViroPharma Inc. in 2008, he consulted on the Cinryze commercial launch and expansion as well as investor relations activities for ViroPharma. Dr. Kalfus is consulting Medical Director at RedHill Biopharma Ltd. and directs two phase III clinical programs. His other positions have included Aetna/US Healthcare (Medical Director), Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement).

Dr. Kalfus completed residency in Internal Medicine at Long Island Jewish Medical Center and graduated from Albert Einstein College of Medicine with an M.D. and Columbia University with a B.A. in Biology.

 
Andrew McDonald, PhD    Partner   Andrew co-founded LifeSci Partners in 2010 which has since grown to employ 100+ healthcare professionals offering a broad range of advisory services to more than 150 corporate clients in the life sciences sector. As a scientist and former equity analyst, Andrew has a strong understanding of transformative pharmaceutical products and technologies in all stages of development, and also has a strong network across healthcare institutional investors and executives. Prior to LifeSci, Andrew worked at Great Point Partners, a life sciences hedge fund, and headed healthcare research and was a publishing biotechnology analyst at ThinkEquity Partners. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics and at Pfizer.  Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.

Andrew McDonald, PhD

Partner

Andrew co-founded LifeSci Partners in 2010 which has since grown to employ 100+ healthcare professionals offering a broad range of advisory services to more than 150 corporate clients in the life sciences sector. As a scientist and former equity analyst, Andrew has a strong understanding of transformative pharmaceutical products and technologies in all stages of development, and also has a strong network across healthcare institutional investors and executives. Prior to LifeSci, Andrew worked at Great Point Partners, a life sciences hedge fund, and headed healthcare research and was a publishing biotechnology analyst at ThinkEquity Partners. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics and at Pfizer.

Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.

 
Michael Rice    Partner   Michael Rice has experience in portfolio management, corporate management, investment banking and capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital, Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also was a Managing Director at ThinkEquity Partners where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions, many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Banc of America serving large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist and Senior Managing Director at Bear Stearns.  Michael graduated from the University of Maryland with a degree in Economics and serves on the boards of Navidea (NAVD) and RDD Pharma.

Michael Rice

Partner

Michael Rice has experience in portfolio management, corporate management, investment banking and capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital, Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also was a Managing Director at ThinkEquity Partners where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions, many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Banc of America serving large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist and Senior Managing Director at Bear Stearns.

Michael graduated from the University of Maryland with a degree in Economics and serves on the boards of Navidea (NAVD) and RDD Pharma.

 
Julie Mauser    Business Development   Julie joins LifeSci with more than 10 years of experience working with institutional investors. Most recently, Julie was Head of Business Development at Atrato Advisors, an outsourced consultant for alternative investments. Prior to Atrato Advisors, Julie was Vice President of Marketing at Par-Four Investment Management, a credit-focused alternative investment manager. At Par-Four, she coordinated marketing and investor relations, cultivating relationships with family office and institutional clients. Previously, Julie was part of the Capital Introduction team at Jefferies & Company, where she was in charge of growing and maintaining the firm’s relationships with family office investors. She started her career as a member of JP Morgan’s prime brokerage team.  Julie grew up competitive figure skating and continues her love of the sport by volunteering to coach NYC elementary school children who are learning to skate. She graduated magna cum laude from Lehigh University with a Bachelor of Science degree in Marketing.

Julie Mauser

Business Development

Julie joins LifeSci with more than 10 years of experience working with institutional investors. Most recently, Julie was Head of Business Development at Atrato Advisors, an outsourced consultant for alternative investments. Prior to Atrato Advisors, Julie was Vice President of Marketing at Par-Four Investment Management, a credit-focused alternative investment manager. At Par-Four, she coordinated marketing and investor relations, cultivating relationships with family office and institutional clients. Previously, Julie was part of the Capital Introduction team at Jefferies & Company, where she was in charge of growing and maintaining the firm’s relationships with family office investors. She started her career as a member of JP Morgan’s prime brokerage team.

Julie grew up competitive figure skating and continues her love of the sport by volunteering to coach NYC elementary school children who are learning to skate. She graduated magna cum laude from Lehigh University with a Bachelor of Science degree in Marketing.